CN104547718B - A kind of pharmaceutical composition preventing and treating fracture of children internal fixation postoperative infection - Google Patents
A kind of pharmaceutical composition preventing and treating fracture of children internal fixation postoperative infection Download PDFInfo
- Publication number
- CN104547718B CN104547718B CN201510046473.XA CN201510046473A CN104547718B CN 104547718 B CN104547718 B CN 104547718B CN 201510046473 A CN201510046473 A CN 201510046473A CN 104547718 B CN104547718 B CN 104547718B
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- radix
- folium
- cortex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition preventing and treating fracture of children internal fixation postoperative infection, be made up of the material of following weight portion: Stigma Maydis 1 10 parts, Folium Rhododendri Simsii 1 10 parts, Radix Platycodonis 1 10 parts, Periostracum Cicadae 5 15 parts, great Ye Herba chenopodii 5 10 parts, Cortex Firmianae 10 20 parts, Herba Kalimeridis 1 10 parts, Herba Gynurae bicoloris 1 10 parts, Radix Helianthi 5 15 parts, Cortex Albiziae 5 15 parts, Monas cuspurpureus Went 1 10 parts, Herba Lysimachiae Candidae 10 20 parts, salvia bowleyana Dunn 1 10 parts, Flos Echinopsis latifolii 1 10 parts, Radix Glycyrrhizae 1 10 parts, Folium Raphani 5 15 parts, Radix Isatidis 10 20 parts, Folium Isatidis 5 15 parts, Cortex Phellodendri 10 20 parts, Herba Eupatorii Heterophylli 1 10 parts, cercis root 1 10 parts, Herba Inulae cappae root 10 20 parts, Caulis Lonicerae 5 15 parts.Pharmaceutical composition of the present invention can promote wound healing and tissue regeneration, and has certain antibacterial, bactericidal action, Be very effective and safe and reliable, clinic application and promoting.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of pharmaceutical composition preventing and treating fracture of children internal fixation postoperative infection.
Background technology
Child's nature are active, full of vitality, and like quarrelling and fighting noisily and jump, self-control is poor, to identification and the judgement deficiency of danger, are easy to the wound that meets accident.Wherein fracture is one of common type of accident trauma.The skeleton of child is still in growth stage, and unexpected generations such as running, play, fall all can cause fracture, affects the normal development in extremity or joint.Internal fixation of fracture is the routine operation resetted after fracture, knochenbruch couples together with inside-fixtures such as metallic screw, steel plate, hone lamellas by it, the anatomical reduction of fracturing can be kept preferably, be conducive to the functional exercise of hindering limb, reduce the complication because long-term bed causes.But row fracture fixation operations, fracture site is unstable, the existence of inside-fixture, fracture infant soft tissue injury and wound pollutes and the factor such as hypoimmunity all easily causes postoperative infection.It is one of common and serious complication of orthopaedics that fracture fixation operations infects.Infection can cause wound redness, suppurate and pain discomfort, and add misery and financial burden to patient, more also can not cause chronic osteomyelitis and Infected nonunion for a long time, need to take out the capable secondary art of inside-fixture, severe patient may face the risk of amputation.
The conventional treatment method that current doctor trained in Western medicine infects for fracture fixation operations is clinically that application is enough, the control of wide spectrum, potent antibiotic is infected.But long term systemic application antibiotic likely brings a series of side reaction, and infection topica concentration is often not high, makes utilization ratio of drug very low.The traditional Chinese medical science then generally believes that fracture fixation operations infects and belongs to " pyogenic infection of the bone " category, many by acute delay, treatment is eliminated the phlegm with temperature compensation QI and blood, change addiction, resolving and invigoration therapies being applied simultaneously is advisable, and compare doctor trained in Western medicine, Chinese medicine makes simply, uses no pain, and infant is easy to accept, and has no adverse reaction, cure rate is high, more safety and be easy to operation.
Summary of the invention
The object of this invention is to provide a kind of pharmaceutical composition preventing and treating fracture of children internal fixation postoperative infection.
In order to realize object of the present invention, the invention provides a kind of pharmaceutical composition preventing and treating fracture of children internal fixation postoperative infection, it is made up of the material of following weight portion: Stigma Maydis 1 ?10 parts, Folium Rhododendri Simsii 1 ?10 parts, Radix Platycodonis 1 ?10 parts, Periostracum Cicadae 5 ?15 parts, great Ye Herba chenopodii 5 ?10 parts, Cortex Firmianae 10 ?20 parts, Herba Kalimeridis 1 ?10 parts, Herba Gynurae bicoloris 1 ?10 parts, Radix Helianthi 5 ?15 parts, Cortex Albiziae 5 ?15 parts, Monas cuspurpureus Went 1 ?10 parts, Herba Lysimachiae Candidae 10 ?20 parts, salvia bowleyana Dunn 1 ?10 parts, Flos Echinopsis latifolii 1 ?10 parts, Radix Glycyrrhizae 1 ?10 parts, Folium Raphani 5 ?15 parts, Radix Isatidis 10 ?20 parts, Folium Isatidis 5 ?15 parts, Cortex Phellodendri 10 ?20 parts, Herba Eupatorii Heterophylli 1 ?10 parts, cercis root 1 ?10 parts, Herba Inulae cappae root 10 ?20 parts, Caulis Lonicerae 5 ?15 parts.
Preferably, the pharmaceutical composition of control fracture of children internal fixation postoperative infection of the present invention is made up of the material of following weight portion: Stigma Maydis 5 parts, Folium Rhododendri Simsii 10 parts, Radix Platycodonis 8 parts, Periostracum Cicadae 12 parts, great Ye Herba chenopodii 8 parts, Cortex Firmianae 15 parts, Herba Kalimeridis 8 parts, Herba Gynurae bicoloris 10 parts, Radix Helianthi 10 parts, Cortex Albiziae 12 parts, 5 parts, Monas cuspurpureus Went, Herba Lysimachiae Candidae 15 parts, salvia bowleyana Dunn 5 parts, Flos Echinopsis latifolii 5 parts, 8 parts, Radix Glycyrrhizae, Folium Raphani 10 parts, Radix Isatidis 15 parts, Folium Isatidis 10 parts, Cortex Phellodendri 15 parts, Herba Eupatorii Heterophylli 5 parts, cercis root 5 parts, Herba Inulae cappae root 15 parts, Caulis Lonicerae 10 parts.
More preferably, described pharmaceutical composition can be tablet, dispersible tablet, capsule, soft capsule or lotion.
The present invention also provides the purposes of compositions in the medicine of preparation control fracture of children internal fixation postoperative infection, described compositions is made up of the material of following weight portion: Stigma Maydis 1 ?10 parts, Folium Rhododendri Simsii 1 ?10 parts, Radix Platycodonis 1 ?10 parts, Periostracum Cicadae 5 ?15 parts, great Ye Herba chenopodii 5 ?10 parts, Cortex Firmianae 10 ?20 parts, Herba Kalimeridis 1 ?10 parts, Herba Gynurae bicoloris 1 ?10 parts, Radix Helianthi 5 ?15 parts, Cortex Albiziae 5 ?15 parts, Monas cuspurpureus Went 1 ?10 parts, Herba Lysimachiae Candidae 10 ?20 parts, salvia bowleyana Dunn 1 ?10 parts, Flos Echinopsis latifolii 1 ?10 parts, Radix Glycyrrhizae 1 ?10 parts, Folium Raphani 5 ?15 parts, Radix Isatidis 10 ?20 parts, Folium Isatidis 5 ?15 parts, Cortex Phellodendri 10 ?20 parts, Herba Eupatorii Heterophylli 1 ?10 parts, cercis root 1 ?10 parts, Herba Inulae cappae root 10 ?20 parts, Caulis Lonicerae 5 ?15 parts.
Preferably, described compositions is made up of the material of following weight portion: Stigma Maydis 5 parts, Folium Rhododendri Simsii 10 parts, Radix Platycodonis 8 parts, Periostracum Cicadae 12 parts, great Ye Herba chenopodii 8 parts, Cortex Firmianae 15 parts, Herba Kalimeridis 8 parts, Herba Gynurae bicoloris 10 parts, Radix Helianthi 10 parts, Cortex Albiziae 12 parts, 5 parts, Monas cuspurpureus Went, Herba Lysimachiae Candidae 15 parts, salvia bowleyana Dunn 5 parts, Flos Echinopsis latifolii 5 parts, 8 parts, Radix Glycyrrhizae, Folium Raphani 10 parts, Radix Isatidis 15 parts, Folium Isatidis 10 parts, Cortex Phellodendri 15 parts, Herba Eupatorii Heterophylli 5 parts, cercis root 5 parts, Herba Inulae cappae root 15 parts, Caulis Lonicerae 10 parts.
More preferably, described medicine can be tablet, dispersible tablet, capsule, soft capsule or lotion.
In the present compositions, Flos Echinopsis latifolii, Caulis Lonicerae, cercis root are monarch drug; Stigma Maydis, Radix Isatidis, Cortex Albiziae, Folium Isatidis, Herba Eupatorii Heterophylli, Folium Raphani are ministerial drug; Folium Rhododendri Simsii, Radix Platycodonis, Periostracum Cicadae, great Ye Herba chenopodii, Cortex Firmianae, Herba Kalimeridis, Herba Gynurae bicoloris, Radix Helianthi, Monas cuspurpureus Went, Herba Lysimachiae Candidae, salvia bowleyana Dunn, Cortex Phellodendri, Herba Inulae cappae root are adjuvant drug; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, for making medicine.
Pharmaceutical composition of the present invention is based on dissipating blood stasis, promoting blood circulation to remove obstruction in the collateral, the reducing swelling and alleviating pain of detoxifying, have warming YANG and invigorating blood, expelling wind and removing dampness concurrently, wound healing and tissue regeneration can be promoted, and have certain antibacterial, bactericidal action, control fracture of children Ineffective internal fixation infectious effect is remarkable and safe and reliable, clinic application and popularization.
Detailed description of the invention
The present invention is further illustrated below by embodiment.One skilled in the art will appreciate that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modification that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment lotion of the present invention
Take Stigma Maydis 50 grams, Folium Rhododendri Simsii 100 grams, Radix Platycodonis 80 grams, Periostracum Cicadae 120 grams, great Ye Herba chenopodii 80 grams, Cortex Firmianae 150 grams, Herba Kalimeridis 80 grams, Herba Gynurae bicoloris 100 grams, Radix Helianthi 100 grams, Cortex Albiziae 120 grams, 50 grams, Monas cuspurpureus Went, Herba Lysimachiae Candidae 150 grams, salvia bowleyana Dunn 50 grams, Flos Echinopsis latifolii 50 grams, 80 grams, Radix Glycyrrhizae, Folium Raphani 100 grams, Radix Isatidis 150 grams, Folium Isatidis 100 grams, Cortex Phellodendri 150 grams, Herba Eupatorii Heterophylli 50 grams, cercis root 50 grams, Herba Inulae cappae root 150 grams, Caulis Lonicerae 100 grams, add 80000 ml waters, reflux 3 hours in the flask that condensing tube is housed, then filter, obtain filtrate 1 and filtering residue 1, 2) in filtering residue 1, add 20000 ml waters, heat 1 hour in the flask that condensing tube is housed, filter, obtain filtrate 2 and filtering residue 2, 3) merge described filtrate 1, filtrate 2, be cooled to room temperature, obtain final product.
The effect of experimental example pharmaceutical composition of the present invention
1, this group of physical data fracture fixation operations infects 50 children, is divided into observation group 28 example and matched group 22 example.Observation group infant man 21 example, female 7 example, the age 3 ?between 10 years old, average 7.2 years old; Infect average (4.62 ± 2.48) cm of area
2; Infection site is in forearm and hand 6 example, and leg 14 example, foot 8 is routine.Matched group infant man 16 example, female 6 example, the age 2.5 ?between 9 years old, average 6.8 years old; Infect average (4.28 ± 1.92) cm of area
2; Infection site is in forearm and hand 4 example, and leg 12 example, foot 6 is routine.All infants are all without the sign of fever heating systemic infection.The physical data comparing difference not statistically significant (p>0.05) of two groups of infants.
2, method observation group uses lotion soak of the present invention prepared by embodiment, is pressed in infection site, each 2 minutes with the yarn block of the lotion being impregnated with 300 milliliters of the present invention.Treat 2 every day.
Matched group uses furacilin aqueous solution (production of the Nanchang white clouds pharmaceutcal corporation, Ltd) soak of 0.01 % by weight, is pressed in infection site, each 2 minutes with the yarn block of the solution being impregnated with 300 milliliters.Treat 2 every day.
Method is the same.
Two groups was all a course for the treatment of with 2 weeks, observed 1 course for the treatment of.
3, evaluation index recovery from illness: infective wound surface all healed, without false healing phenomenons such as empyemas under crust, partial gall disappears, suffering limb functional rehabilitation; Effective: to infect area and reduce >75%, without purulent secretion, partial gall disappears, and suffering limb function is recovered to some extent; Effective: infect area reduce 25% ?75%, purulent secretion obviously reduces, and partial gall and suffering limb function take a favorable turn; Invalid: wound surface area reduces <25% and without obviously reducing trend, purulent secretion is without obvious minimizing, and partial gall and suffering limb function are without being clearly better.
The standard of granulation upgrowth situation is divided into 3 grades.I level: infective wound surface heals; II level: granulation granule is cerise, that touches is easily hemorrhage; III level: granulation color is dark, have edema, and that touches is not easily hemorrhage.
4, statistical method adopts SPSS13.0 statistical software to carry out data analysis.Measurement data with
represent, compare between group and adopt t inspection; Enumeration data adopts χ
2inspection.Be that difference has statistical significance with p<0.05.
5, result
Two groups of therapeutic effect relatively in table 1 and table 2.
Table 1 liang group comparitive study
Note: compare with matched group, * p<0.05
Observation group is better than matched group (p<0.05) at treatment 2 weeks rear granulation growing states.
A table 2 liang group granulation growing state compares
Claims (2)
1. prevent and treat the pharmaceutical composition of fracture of children internal fixation postoperative infection for one kind, it is characterized in that being made up of the material of following weight portion: Stigma Maydis 1 ?10 parts, Folium Rhododendri Simsii 1 ?10 parts, Radix Platycodonis 1 ?10 parts, Periostracum Cicadae 5 ?15 parts, great Ye Herba chenopodii 5 ?10 parts, Cortex Firmianae 10 ?20 parts, Herba Kalimeridis 1 ?10 parts, Herba Gynurae bicoloris 1 ?10 parts, Radix Helianthi 5 ?15 parts, Cortex Albiziae 5 ?15 parts, Monas cuspurpureus Went 1 ?10 parts, Herba Lysimachiae Candidae 10 ?20 parts, salvia bowleyana Dunn 1 ?10 parts, Flos Echinopsis latifolii 1 ?10 parts, Radix Glycyrrhizae 1 ?10 parts, Folium Raphani 5 ?15 parts, Radix Isatidis 10 ?20 parts, Folium Isatidis 5 ?15 parts, Cortex Phellodendri 10 ?20 parts, Herba Eupatorii Heterophylli 1 ?10 parts, cercis root 1 ?10 parts, Herba Inulae cappae root 10 ?20 parts, Caulis Lonicerae 5 ?15 parts.
2. the pharmaceutical composition of control fracture of children internal fixation postoperative infection according to claim 1, it is made up of the material of following weight portion: Stigma Maydis 5 parts, Folium Rhododendri Simsii 10 parts, Radix Platycodonis 8 parts, Periostracum Cicadae 12 parts, great Ye Herba chenopodii 8 parts, Cortex Firmianae 15 parts, Herba Kalimeridis 8 parts, Herba Gynurae bicoloris 10 parts, Radix Helianthi 10 parts, Cortex Albiziae 12 parts, 5 parts, Monas cuspurpureus Went, Herba Lysimachiae Candidae 15 parts, salvia bowleyana Dunn 5 parts, Flos Echinopsis latifolii 5 parts, 8 parts, Radix Glycyrrhizae, Folium Raphani 10 parts, Radix Isatidis 15 parts, Folium Isatidis 10 parts, Cortex Phellodendri 15 parts, Herba Eupatorii Heterophylli 5 parts, cercis root 5 parts, Herba Inulae cappae root 15 parts, Caulis Lonicerae 10 parts.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510046473.XA CN104547718B (en) | 2015-01-30 | 2015-01-30 | A kind of pharmaceutical composition preventing and treating fracture of children internal fixation postoperative infection |
| CN201510279661.7A CN104857338A (en) | 2015-01-30 | 2015-01-30 | Preparation method of medicine for preventing and treating infection after internal fixation of fracture in children |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510046473.XA CN104547718B (en) | 2015-01-30 | 2015-01-30 | A kind of pharmaceutical composition preventing and treating fracture of children internal fixation postoperative infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510279661.7A Division CN104857338A (en) | 2015-01-30 | 2015-01-30 | Preparation method of medicine for preventing and treating infection after internal fixation of fracture in children |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104547718A CN104547718A (en) | 2015-04-29 |
| CN104547718B true CN104547718B (en) | 2015-09-09 |
Family
ID=53065489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510279661.7A Pending CN104857338A (en) | 2015-01-30 | 2015-01-30 | Preparation method of medicine for preventing and treating infection after internal fixation of fracture in children |
| CN201510046473.XA Expired - Fee Related CN104547718B (en) | 2015-01-30 | 2015-01-30 | A kind of pharmaceutical composition preventing and treating fracture of children internal fixation postoperative infection |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510279661.7A Pending CN104857338A (en) | 2015-01-30 | 2015-01-30 | Preparation method of medicine for preventing and treating infection after internal fixation of fracture in children |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN104857338A (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003066745A1 (en) * | 2002-02-05 | 2003-08-14 | Sakura Color Products Corporation | Water-based bright colorant composition |
| CN1899535A (en) * | 2006-06-28 | 2007-01-24 | 广东皮宝制药有限公司 | Method for preparing dermopathic blood toxic capsule |
| US20080260871A1 (en) * | 2007-04-18 | 2008-10-23 | Fruitman Clinton O | Method and composition for infusing herbal extracts and pharmaceuticals through the skin |
| CN102198232B (en) * | 2011-05-05 | 2012-08-22 | 周升峰 | Method for preparing Chinese medicine for treating suppurative otitis media |
| CN104042765A (en) * | 2014-06-24 | 2014-09-17 | 郑东明 | Medicine for promoting postoperative fracture recovery and preparation method of medicine |
-
2015
- 2015-01-30 CN CN201510279661.7A patent/CN104857338A/en active Pending
- 2015-01-30 CN CN201510046473.XA patent/CN104547718B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN104857338A (en) | 2015-08-26 |
| CN104547718A (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102327478B (en) | Pharmaceutical composition for treating burns and scalds and preparation method thereof | |
| CN101919927B (en) | Spray for promoting scald healing | |
| CN102357164B (en) | Medicine composition for clinical care of burns and preparation method thereof | |
| CN101732591B (en) | Sores plaster | |
| CN106668631A (en) | Chinese herbal medicine for treating rhinitis | |
| CN102274353B (en) | Traditional Chinese preparation for treating ulcers | |
| CN101390998A (en) | External medicine for treating osteomyelitis | |
| CN104547718B (en) | A kind of pharmaceutical composition preventing and treating fracture of children internal fixation postoperative infection | |
| CN105250712B (en) | A kind of Chinese medicine composition for treating bedsore | |
| CN102793904A (en) | Preparation method for traditional Chinese medicine lotion for treatment of confusing-type closed fracture | |
| CN102552560B (en) | Compound combination medicament for effectively treating hand-foot-and-mouth disease | |
| CN104784482A (en) | Traditional Chinese medicine for treating chronic pyogenic osteomyelitis | |
| CN106581379A (en) | Spraying agent for promoting blood circulation and removing stasis and preparation method thereof | |
| CN104857303A (en) | Preparation method of medicine for treating infantile eczema | |
| CN104815029B (en) | A kind of drug and preparation method thereof for treating tinea pedis | |
| CN101979088A (en) | Medicament for treating cauma and empyrosis | |
| CN106581380A (en) | External preparation capable of promoting blood circulation to remove blood stasis and preparation method of external preparation | |
| CN106109854A (en) | A kind of pharmaceutical composition promoting skin wound healing | |
| CN105168945A (en) | External ointment for promoting fracture healing and preparation method of external ointment | |
| CN104398992A (en) | Traditional Chinese medicinal preparation for treating infectious trauma | |
| CN105079215A (en) | Medicine composition for treating diabetic foot ulcer | |
| CN104758378A (en) | Traditional Chinese medicine for treating postpartum blood stasis | |
| CN103610743B (en) | One treats phthisical external Chinese medicinal liquid | |
| CN103638173B (en) | The Chinese medicine for outer use for the treatment of decubital ulcer | |
| CN103230526A (en) | Preparation method of traditional Chinese medicine lotion for treating felon caused by stagnation of qi and blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HE WENBO Free format text: FORMER OWNER: ZHANG XIMEI Effective date: 20150814 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: He Wenbo Inventor before: Zhang Ximei |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG XIMEI TO: HE WENBO |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150814 Address after: No. 79 pediatric surgery Affiliated Hospital of Jining Medical College 272100 Shandong province Jining Guhuai Road Applicant after: He Wenbo Address before: 054001 Xingtai Development Zone, Hebei, South Road, No. 168 Applicant before: Zhang Ximei |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150909 Termination date: 20160130 |
|
| EXPY | Termination of patent right or utility model |